Cannabis Use Disorder Market By Treatment Type (Non-Pharmacological Treatment, Pharmacological Treatment); By Delivery Channel (Outpatient Clinics, Primary Care, Digital Therapeutics, University Programs); By Patient Demographics – Age Group (18–29 Years, 30–45 Years, 45+ Years); By Patient Demographics – Gender (Male, Female); By Geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Cannabis Use Disorder Market Size and How Is the Treatment Landscape Evolving?  – (Updated On: 06-Sep-2026)

The Global Cannabis Use Disorder Market was valued at USD 1.56 billion in 2025 and is projected to reach USD 2.46 billion by 2032, expanding at a CAGR of 6.73% during 2026–2032, according to Strategic Market Research. Cannabis use disorder is a clinical condition in which cannabis use becomes difficult to control and continues despite significant health, social, occupational, or other negative consequences. Symptoms can include craving, tolerance, withdrawal, unsuccessful efforts to reduce consumption, and continued use despite harm.

 

High-frequency cannabis consumption, initiation during adolescence, and exposure to products containing high concentrations of THC increase the likelihood of developing CUD. The CDC estimates that approximately 3 in 10 cannabis users develop CUD, with risk increasing among people who begin using cannabis at younger ages or consume it regularly.

 

CUD represents a substantial public health burden. In the United States, approximately 19.3 million people aged 12 years and older had past-year cannabis use disorder in 2025. Among U.S. adults, recent research has estimated CUD prevalence at approximately 9.3% among men and 5.6% among women. Globally, approximately 22.6 million people were estimated to have CUD in 2021. Cannabis is also the world's most widely used drug, with an estimated 256 million users globally in 2024.

 

Fatal overdose caused by cannabis alone is extremely uncommon. A CDC analysis published in September 2026 examined 209,166 overdose deaths occurring from January 2021 through June 2025 across 31 U.S. states and Washington, D.C. Cannabis was detected in 43,880 deaths, representing 21.0% of the total. However, detection does not establish cannabis as the cause of death. Cannabis was listed as contributing to death in only 0.8% of all overdose deaths, or 1,687 cases, and was the only drug involved in just nine deaths, equivalent to 0.004%.

 

Polysubstance use accounted for most cannabis-positive overdose deaths. Among deaths in which cannabis was detected, 73.5% also involved illegally manufactured fentanyls and 60.4% involved stimulants such as cocaine or methamphetamine. The CDC therefore concluded that cannabis detection in overdose deaths primarily reflects polysubstance use rather than fatal toxicity from cannabis alone.

 

There is currently no FDA-approved medication specifically for CUD. Behavioral interventions remain the main treatment approach, particularly cognitive behavioral therapy, motivational enhancement therapy, and contingency management. Several medications, including N-acetylcysteine, gabapentin, varenicline, nabilone, nabiximols, cannabidiol, and other compounds, have been evaluated experimentally or used off-label, but none has established FDA approval for CUD.

 

The therapeutic pipeline is attempting to address this treatment gap. AEF0117, a CB1 signaling-specific inhibitor, has completed Phase 2B evaluation, although the trial did not achieve its primary and major secondary endpoints. PP-01 is being developed for cannabis withdrawal symptoms in patients with CUD and has received FDA Fast Track designation while advancing into Phase III development.

 

The large affected population, increasing exposure to high-potency cannabis, substantial polysubstance-use burden, absence of an approved pharmacological treatment, and advancement of investigational therapies are increasing demand for effective CUD management. Greater diagnosis, behavioral treatment utilization, and development of the first targeted medicines could further support market expansion through 2032.

 

Cannabis Use Disorder Market Leading and Fastest-Growing Segment Analysis

By Treatment Type:

• Leading Segment – Non-Pharmacological Treatment: Non-pharmacological treatment led the Cannabis Use Disorder Market with approximately 72.5% share in 2025. Its dominance reflects the established clinical use of cognitive behavioral therapy, motivational enhancement therapy, contingency management, counseling, and structured addiction programs as the principal CUD treatment approaches.

• Fastest-Growing Segment – Pharmacological Treatment: Pharmacological treatment is projected to record the fastest CAGR of approximately 8.5% during 2026–2032. Growth is supported by greater therapeutic-development activity, including investigational candidates targeting cannabis withdrawal and CUD, which could add a medication-based component to the existing behavioral-care pathway.

 

By Delivery Channel:

• Leading Segment – Outpatient Clinics: Outpatient clinics held the largest share at approximately 41.0% in 2025. Their leadership is supported by the suitability of ambulatory settings for repeat counseling, behavioral therapy, psychiatric assessment, relapse management, and continued substance-use treatment without hospitalization.

• Fastest-Growing Segment – Digital Therapeutics: Digital therapeutics are projected to expand at the fastest CAGR of approximately 9.4% during 2026–2032. Remote behavioral interventions, digitally delivered therapy, and hybrid clinician-supported platforms can improve treatment accessibility and provide scalable engagement for patients who may not regularly attend specialist addiction centers.

 

By Patient Demographics – Age Group:

• Leading and Fastest-Growing Segment – 18–29 Years: Adults aged 18–29 dominated the market with approximately 46.5% share in 2025 and are also projected to record the fastest CAGR of approximately 7.2% during 2026–2032. The segment's position reflects the comparatively high prevalence of cannabis use disorder among younger adults and their greater relevance to outpatient counseling, university-based intervention, digital treatment, and early behavioral-health engagement.

 

By Patient Demographics – Gender:

• Leading Segment – Male: Male patients accounted for approximately 68.0% of the Cannabis Use Disorder Market in 2025. Their dominant position reflects the comparatively higher representation of males in cannabis-use and cannabis-treatment populations across several national treatment datasets.

• Fastest-Growing Segment – Male: The male segment is also projected to record the higher CAGR at approximately 6.8% during 2026–2032, compared with approximately 6.5% for females. Continued treatment utilization across outpatient addiction services and behavioral-health programs supports its larger commercial contribution.

 

By Geography:

• Leading Region – North America: North America led the Cannabis Use Disorder Market with approximately 48.5% share in 2025. The region benefits from a large identified CUD patient population, established behavioral-health reimbursement, specialist addiction-treatment infrastructure, strong clinical research activity, and advancing therapeutic programs.

• Fastest-Growing Region – Asia Pacific: Asia Pacific is projected to register the fastest CAGR of approximately 7.8% during 2026–2032. Expansion is supported by developing behavioral-health and addiction-treatment infrastructure, broader availability of community-based care, and measurable cannabis-treatment activity in markets such as Australia.

 

Cannabis Use Disorder Market Treatment Type Analysis Shows Behavioral Care Leading While Pharmacotherapy Advances

Non-pharmacological treatments, primarily psychosocial interventions such as behavioral therapies and counseling, represent the cornerstone of Cannabis Use Disorder (CUD) management due to the absence of FDA-approved medications specifically indicated for this condition. In 2025, this segment accounted for approximately 72.5% of the CUD treatment market, valued at USD 1.131 billion. Supported by increasing adoption of evidence-based therapies and growing awareness of behavioral health approaches, the segment is expected to expand at a CAGR of approximately 6.1% during 2026–2032.

Pharmacological treatment accounted for approximately 27.5% of the market in 2025, valued at around USD 429.0 million, and is expected to expand at a CAGR of approximately 8.5% through 2032. However, despite increasing demand, there are currently no FDA-approved medications specifically indicated for Cannabis Use Disorder (CUD) or cannabis withdrawal management. As a result, pharmacotherapy remains an investigational approach, with ongoing research focused on developing effective and targeted treatment options to address unmet clinical needs.

 

 Cannabis Use Disorder Market Delivery Channel Analysis Highlights Outpatient and Digital Care Expansion

Outpatient clinics represented a significant share of the Cannabis Use Disorder (CUD) market, accounting for approximately 41.0% of the market value, equivalent to USD 639.6 million in 2025. This segment is expected to grow at a CAGR of around 6.2% between 2026 and 2032, driven by increasing demand for accessible and flexible treatment options. Outpatient care enables individuals with CUD to receive counseling, behavioral therapies, and recovery support while continuing their work, education, and family commitments, making it a preferred treatment approach.

Primary care accounted for approximately 26.0% of the market, valued at USD 405.6 million in 2025, and is expected to expand at a CAGR of around 5.8%. This segment plays a critical role in addressing Cannabis Use Disorder (CUD), as primary care providers are often the first point of contact for patients. Through routine screening, early identification, patient education, brief interventions, and coordinated referrals to specialized services, they help improve timely diagnosis, treatment access, and long-term management of CUD.

Digital therapeutics (DTx) represented approximately 18.5% of the market, valued at USD 288.6 million in 2025, and are expected to witness the fastest delivery-channel growth with a CAGR of around 9.4%. These evidence-based software solutions use smartphone and computer platforms to support the treatment of Cannabis Use Disorder (CUD) by providing clinically validated behavioral interventions, personalized therapy programs, and continuous patient progress monitoring. Their accessibility, scalability, and ability to deliver remote care are driving rapid adoption in CUD management.

University programs represented approximately 14.5% of the market, equivalent to USD 226.2 million in 2025, and are projected to grow at a CAGR of approximately 5.4%. University health and counseling services are positioned close to younger populations with comparatively high CUD prevalence and can combine screening, brief intervention, behavioral care, and specialist referral. Universities also contribute to therapeutic innovation: Johns Hopkins University is recruiting a proof-of-concept study evaluating psilocybin-assisted treatment in treatment-seeking individuals with CUD, although the program remains investigational and is not a commercial treatment.

 

Cannabis Use Disorder Market Patient Demographics Show the Largest Commercial Concentration in Younger Adults

Adults aged 18–29 accounted for approximately 46.5% of the Cannabis Use Disorder Market, representing USD 725.4 million in 2025, and are projected to expand at a CAGR of approximately 7.2% during 2026–2032. SAMHSA's narrower 18–25 age category recorded a 14.1% past-year CUD prevalence in 2025, corresponding to 5.1 million people and the highest percentage among the age groups reported. Australian treatment evidence points in the same direction: 34% of clients treated for cannabis as their principal drug of concern in 2024–25 were aged 20–29. The segment therefore has particular relevance for outpatient behavioral care, digital engagement, university-linked intervention, and relapse-prevention services.

Patients aged 30–45 represented approximately 34.0% of the market, equivalent to USD 530.4 million in 2025, and are expected to grow at a CAGR of approximately 6.5%. This cohort represents a sizeable adult treatment population in which persistent use, repeated attempts to reduce cannabis, psychiatric comorbidity, employment-related functional effects, and previous treatment exposure can sustain recurring behavioral-health utilization. Compared with younger adults, the commercial pathway is more likely to involve primary care, mental-health professionals, outpatient addiction services, and coordinated treatment of co-occurring conditions.

Adults aged 45 years and older accounted for approximately 19.5% of the market, representing USD 304.2 million in 2025, and are projected to expand at a CAGR of approximately 5.4%. The group remains smaller than younger patient segments but can require more integrated treatment because cannabis use may coexist with chronic disease, psychiatric disorders, chronic pain, or multiple medications. These factors increase the relevance of primary-care-led assessment and coordinated behavioral-health management rather than youth-oriented intervention models.

 

Gender-Based Market Dynamics Highlights Cannabis Use Disorder Market

Male patients accounted for approximately 68.0% of the Cannabis Use Disorder Market, representing USD 1.0608 billion in 2025, and are projected to expand at a CAGR of approximately 6.8%. Australian data provide a treatment-system reference point: 59% of the 17,863 clients treated for cannabis as their principal drug of concern in 2024–25 were male. Pharmacotherapy research has also historically included predominantly male populations; a 2025 review found that most participants were male in 32 of the 37 included randomized studies. The higher market share therefore reflects both treatment utilization and the demographic composition of much of the existing clinical evidence base.

Female patients represented approximately 32.0% of the market, equivalent to USD 499.2 million in 2025, and are projected to grow at a CAGR of approximately 6.5%. The commercial pathway for this group is increasingly linked to integrated mental-health and primary-care models capable of addressing CUD alongside anxiety, depression, trauma-related conditions, reproductive-health considerations, or other clinical issues when present. Treatment developers will also need broader female representation in trials if future products are intended for widespread use across the full CUD population.

 

Cannabis Use Disorder Market Regional Analysis Shows North America Leading While Asia Pacific Records Faster Expansion

North America accounted for approximately 48.5% of the Cannabis Use Disorder Market, representing USD 756.6 million in 2025, and is projected to expand at a CAGR of approximately 6.4% during 2026–2032. The United States provides the region's largest identifiable clinical base, with 19.3 million people estimated to have past-year CUD in 2025. It also combines specialty addiction centers, VA behavioral-health services, CMS reimbursement pathways, commercial insurance coverage, and active clinical development. PleoPharma's Phase 3 PP-01 program adds a late-stage therapeutic-development component to an already established service market. Canada also contributes a measurable patient population; Statistics Canada reported a 1.4% 12-month CUD prevalence among people aged 15 years or older in 2022.

Europe held approximately 27.0% of the market, equivalent to USD 421.2 million in 2025, and is expected to expand at a CAGR of approximately 6.1%. UNODC estimates that Europe had about 31 million cannabis users in 2024. England's national treatment system demonstrates the conversion of part of this exposure into formal care: 169,542 adults started treatment for drug or alcohol problems during 2024–25, and 37,655 starters reported cannabis as a problem substance. Cannabis was also reported by 13,908 children receiving treatment, representing 86% of all children in the system. France-based Aelis Farma gives the region an additional biotechnology-development presence through AEF0117.

Asia Pacific represented approximately 16.0% of the Cannabis Use Disorder Market, corresponding to USD 249.6 million in 2025, and is projected to register the fastest regional CAGR of approximately 7.8%. Australia provides one of the region's most transparent national treatment datasets. In 2024–25, cannabis was the principal drug of concern in 30,287 treatment episodes, while 17,863 clients received treatment with cannabis recorded as their principal drug. Counseling accounted for 39% of cannabis-related treatment episodes. Australia also reported 1,316 publicly funded alcohol and other drug treatment agencies, providing substantial infrastructure through which cannabis-related behavioral care can be delivered.

Latin America accounted for approximately 5.0% of the market, representing USD 78.0 million in 2025, and is projected to grow at a CAGR of approximately 6.5%. Commercial development remains highly country-specific because specialist addiction capacity, public behavioral-health funding, insurance coverage, and systematic CUD reporting differ considerably across the region. Near-term revenue is therefore more closely linked to behavioral treatment, psychiatric services, and public addiction programs than to a standardized regional pharmaceutical pathway.

Middle East & Africa held approximately 3.5% of the Cannabis Use Disorder Market, equivalent to USD 54.6 million in 2025, and is expected to expand at a CAGR of approximately 5.7%. The region remains the smallest commercial segment because diagnosis, specialist availability, treatment financing, and structured addiction-care networks vary widely. Market development is likely to remain concentrated in larger urban healthcare systems and publicly supported behavioral-health services where formal treatment pathways are available.

 

Cannabis Use Disorder Market Competitive Landscape Is Shifting From Behavioral Services Toward Therapeutic Differentiation

• Axim Biotechnologies, Inc.: A U.S.-based biotechnology company focused on cannabinoid-derived pharmaceutical research and diagnostic technologies. The company explores cannabinoid applications in areas such as pain management, inflammation, and ophthalmic disorders.

• Corbus Pharmaceuticals Holdings, Inc.: Develops therapies targeting the endocannabinoid system and related inflammatory pathways. The company focuses on cannabinoid-based mechanisms to address immune regulation, fibrosis, and chronic disease conditions.

• Cara Therapeutics, Inc.: Researches therapies targeting peripheral nervous system receptors, with a focus on developing treatments for pain, inflammation, and neurological conditions.

• Catalent, Inc.: Provides advanced drug delivery technologies and pharmaceutical development services supporting central nervous system, psychiatric, and cannabinoid-based therapeutic programs.

• Jazz Pharmaceuticals plc (including GW Pharmaceuticals): A global leader in cannabinoid-based medicine following the acquisition of GW Pharmaceuticals. The company develops and commercializes cannabinoid therapies for neurological disorders and central nervous system conditions.

• Almac Group: A UK-based pharmaceutical services company providing clinical trial management, drug development support, and supply chain solutions for neurological and specialty medicine programs.

• Pharmahemp d.o.o.: A Slovenia-based cannabinoid company specializing in standardized cannabinoid extracts and research-driven product development for pharmaceutical and healthcare applications.

• Little Green Pharma Ltd: An Australian medicinal cannabis company with integrated cultivation, manufacturing, and clinical research capabilities. The company focuses on expanding cannabinoid-based medicine development and global market access.

• Botanix Pharmaceuticals Ltd: An Australian biotechnology company developing cannabinoid-derived therapies for dermatological, inflammatory, and systemic conditions through innovative formulations and delivery approaches.

• Aurora Cannabis Inc.: A global medical cannabis company engaged in production, research, and commercialization of cannabinoid-based products. The company supports scientific evaluation of cannabinoids across therapeutic applications.

• Canopy Growth Corporation: A global cannabis-focused company investing in cannabinoid research and pharmaceutical development through innovation programs and subsidiaries targeting therapeutic uses of cannabinoids.

 

Cannabis Use Disorder Breakthrough Outlook: PP-01 Leads the Next Treatment Shift

The strongest near-term pharmaceutical breakthrough is PP-01 from PleoPharma, a once-daily investigational combination of nabilone and gabapentin designed to manage cannabis withdrawal. PP-01 met its Phase 2b primary endpoint for reducing withdrawal symptoms and entered a pivotal Phase 3 study in June 2026, with approximately 420 participants planned. If successful, PP-01 could establish the first dedicated medication-assisted treatment pathway for cannabis withdrawal and create a pharmaceutical revenue category alongside behavioral therapy.

A second innovation frontier is CB1 receptor signaling-specific therapy. Aelis Farma's AEF0117 is designed to selectively modify CB1 signaling without the psychiatric liabilities associated with older CB1 antagonists. However, its Phase 2b primary endpoint was not met, despite encouraging reductions in cannabis consumption among selected highly motivated patients. The mechanism remains promising, but better patient selection and stronger confirmatory efficacy will be required before CB1-SSi drugs can become a major commercial class.

Technology could generate the next major shift through digital therapeutics, remote contingency management, and neuromodulation. NIH's August 2026 CUD initiative specifically prioritizes medications, devices, digital therapeutics, and behavioral interventions capable of progressing toward FDA approval. Digital platforms that combine behavioral therapy, real-time monitoring, incentives, and clinician oversight could scale faster than specialist clinics and improve treatment retention.

The likely breakthrough sequence is therefore PP-01 first, validated digital behavioral platforms second, followed by next-generation CB1 therapies and neuromodulation. The biggest market-changing innovation may ultimately be a combined model in which medication controls withdrawal while digital behavioral care reduces relapse and maintains long-term engagement.

 

Cannabis Use Disorder Market Report Coverage Table

Report Attributes	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.56 Billion
Revenue Forecast in 2032	USD 2.46 Billion
Overall Growth Rate	CAGR of 6.73%
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Delivery Channel, By Patient Demographics – Age Group, By Patient Demographics – Gender, By Geography
By Treatment Type	Non-Pharmacological Treatment, Pharmacological Treatment
By Delivery Channel	Outpatient Clinics, Primary Care, Digital Therapeutics, University Programs
By Patient Demographics – Age Group	18–29 Years, 30–45 Years, 45+ Years
By Patient Demographics – Gender	Male, Female
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	United States, Canada, England, France, Australia
Market Drivers	Large affected population, increasing exposure to high-potency cannabis, substantial polysubstance-use burden, absence of an approved pharmacological treatment, and advancement of investigational therapies
Customization Option	Available upon request